This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Implied Volatility Surging for Dynavax Technologies (DVAX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.
Does Dynavax Technologies (DVAX) Have the Potential to Rally 93.52% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Do Options Traders Know Something About Dynavax Technologies (DVAX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Dynavax Technologies (DVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict an 88.32% Upside in Dynavax Technologies (DVAX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at an 88.3% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Dynavax Technologies (DVAX) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 20% and 3.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies (AQB) delivered earnings and revenue surprises of 1.12% and 52%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 17.65% and 7.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Oculis Holding AG (OCS) Surges 8.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98%
by Zacks Equity Research
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 33.33% and 4.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for July 9th
by Zacks Equity Research
BMWYY, DXC and DVAX have been added to the Zacks Rank #5 (Strong Sell) List on July 9, 2024.
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -40% and 2.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 90.91% and 4.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
by Zacks Equity Research
Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.
Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results
by Zacks Equity Research
Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates. Shares rise.
Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Collegium (COLL) Shares Rise on Financial Outlook for 2024
by Zacks Equity Research
Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.
Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO
by Zacks Equity Research
Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
by Zacks Equity Research
Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why
by Zacks Equity Research
C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.
BEAM Stock Rallies More Than 25% in 3 Months: What Next?
by Zacks Equity Research
BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.
Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology
by Zacks Equity Research
Roche (RHHBY) is set to acquire LumiraDx's Point of Care technology for $295 million and an additional payment of up to $55 million.
Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?
by Zacks Equity Research
Bayer (BAYRY) faced challenges in 2023 as sales declined in the Crop Science division. Pipeline setbacks also weighed on the stock.